Arrowstreet Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $55.3M | Buy |
169,700
+165,645
| +4,085% | +$54M | 0.04% | 395 |
|
|
2025
Q1 | $1.09M | Buy |
+4,055
| New | +$1.09M | ﹤0.01% | 1455 |
|
|
2024
Q3 | – | Sell |
-14,971
| Closed | -$3.64M | – | 1721 |
|
|
2024
Q2 | $3.64M | Buy |
+14,971
| New | +$3.64M | ﹤0.01% | 930 |
|
|
2021
Q1 | – | Sell |
-61,300
| Closed | -$7.97M | – | 2214 |
|
|
2020
Q4 | $7.97M | Buy |
61,300
+57,583
| +1,549% | +$7.48M | 0.01% | 980 |
|
|
2020
Q3 | $541K | Buy |
3,717
+1,517
| +69% | +$221K | ﹤0.01% | 1996 |
|
|
2020
Q2 | $326K | Buy |
+2,200
| New | +$326K | ﹤0.01% | 2084 |
|
|
2020
Q1 | – | Sell |
-3,300
| Closed | -$380K | – | 1844 |
|
|
2019
Q4 | $380K | Buy |
+3,300
| New | +$380K | ﹤0.01% | 1534 |
|
|
2017
Q4 | – | Sell |
-51,485
| Closed | -$6.05M | – | 1227 |
|
|
2017
Q3 | $6.05M | Buy |
+51,485
| New | +$6.05M | 0.02% | 468 |
|
|
2015
Q3 | – | Sell |
-13,274
| Closed | -$1.59M | – | 1333 |
|
|
2015
Q2 | $1.59M | Buy |
+13,274
| New | +$1.59M | 0.01% | 694 |
|
|
2014
Q2 | – | Sell |
-43,081
| Closed | -$2.89M | – | 955 |
|
|
2014
Q1 | $2.89M | Buy |
+43,081
| New | +$2.89M | 0.02% | 568 |
|